According to the NCI website the phospholipid ether-drug conjugate CLR 131 is a radiopharmaceutical composed of a mixture of proprietary phospholipid ethers (CLR 1404) that are covalently linked to the cytotoxic radioisotope iodine I 131 (iodine-131), with potential antineoplastic activity. Check for active clinical trials using this agent.

CLR 131 receives FDA fast track designation in relapsed/refractory multiple myeloma

References (provided by MultipleMyelomaHub on its website)

1. Cellectar Receives FDA Fast Track Designation For CLR 131 In Relapsed Or Refractory Multiple Myeloma. https://myelomabeacon.org/pr/2019/05/13/clr131-fast-track-designation-us-fda/[accessed 2019 May 13]
2. Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1). https://clinicaltrials.gov/ct2/show/NCT02952508[accessed 2019 May 13]
3. Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131. https://globenewswire.com/news-release/2019/02/25/1741555/0/en/Cellectar-Reports-Positive-Top-line-Response-Rate-of-30-from-R-R-Multiple-Myeloma-Cohort-in-Ongoing-Phase-2-Study-of-CLR-131.html[accessed 2019 May 13]
4. Fast Track. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track[accessed 2019 May 13]